Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E Camerini

Showing results (11-20 of 18) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 18 results.
Annals of the Rheumatic Diseases|September 1, 1988
Ankylosing spondylitis with predominant involvement of the cervical spine in a woman with Behçet's syndromeI Olivieri, G Gemignani, F Busoni, et al.
Tumori|September 1, 1996
Malignant pheochromocytoma in multiple endocrine neoplasia type 2B syndrome. Case report and review of the literatureL Scopsi, M R Castellani, M Gullo, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|February 24, 2001
Reducing bioavailable sex hormones through a comprehensive change in diet: the diet and androgens (DIANA) randomized trialF Berrino, C Bellati, G Secreto, et al.
The International Journal of Biological Markers|January 1, 1993
Chronic effects of subcutaneous interleukin-2 therapy on soluble interleukin-2 receptors in advanced small cell lung cancerS Viviani, P M Salvini, P Bidoli, et al.
International Journal of Cardiac Imaging|June 1, 1996
Ambulatory follow-up of aortic dissection: comparison between computed tomography and biplane transesophageal echocardiographyS Maffei, M Baroni, M Terrazzi, et al.
British Journal of Cancer|April 7, 1998
Soluble interleukin-2 receptors (sIL-2R) in Hodgkin's disease: outcome and clinical implicationsS Viviani, E Camerini, V Bonfante, et al.
Cancer|July 1, 1996
A dose-finding study of lanreotide (a somatostatin analog) in patients with colorectal carcinomaA Di Leo, E Bajetta, L Ferrari, et al.
Blood|May 16, 1998
Serum level of the soluble form of the CD30 molecule identifies patients with Hodgkin's disease at high risk of unfavorable outcomeG Nadali, L Tavecchia, E Zanolin, et al.
Pageof 2

Showing results (11-20 of 18) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 18 results.
Annals of the Rheumatic Diseases|September 1, 1988
Ankylosing spondylitis with predominant involvement of the cervical spine in a woman with Behçet's syndromeI Olivieri, G Gemignani, F Busoni, et al.
Tumori|September 1, 1996
Malignant pheochromocytoma in multiple endocrine neoplasia type 2B syndrome. Case report and review of the literatureL Scopsi, M R Castellani, M Gullo, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|February 24, 2001
Reducing bioavailable sex hormones through a comprehensive change in diet: the diet and androgens (DIANA) randomized trialF Berrino, C Bellati, G Secreto, et al.
The International Journal of Biological Markers|January 1, 1993
Chronic effects of subcutaneous interleukin-2 therapy on soluble interleukin-2 receptors in advanced small cell lung cancerS Viviani, P M Salvini, P Bidoli, et al.
International Journal of Cardiac Imaging|June 1, 1996
Ambulatory follow-up of aortic dissection: comparison between computed tomography and biplane transesophageal echocardiographyS Maffei, M Baroni, M Terrazzi, et al.
British Journal of Cancer|April 7, 1998
Soluble interleukin-2 receptors (sIL-2R) in Hodgkin's disease: outcome and clinical implicationsS Viviani, E Camerini, V Bonfante, et al.
Cancer|July 1, 1996
A dose-finding study of lanreotide (a somatostatin analog) in patients with colorectal carcinomaA Di Leo, E Bajetta, L Ferrari, et al.
Blood|May 16, 1998
Serum level of the soluble form of the CD30 molecule identifies patients with Hodgkin's disease at high risk of unfavorable outcomeG Nadali, L Tavecchia, E Zanolin, et al.
Pageof 2